DreamCIS Secures Management Rights of LCS

[Asia Economy Reporter Junho Hwang] DreamCIS, a global contract research organization (CRO), has paved the way to perform tasks across the entire spectrum of clinical trials, from global clinical trial outsourcing to post-marketing surveillance.

DreamCIS, a global CRO, announced on the 1st that it has secured management rights by acquiring shares in 'MediTip,' a specialized company in pharmaceutical and medical device regulatory consulting, followed by acquiring shares in 'LCS,' a specialized non-clinical consulting company.

The new drug development process involves the discovery and selection of candidate substances, followed by non-clinical trials before entering clinical trials. In this process, non-clinical trials are the stage immediately before human application, testing the safety and efficacy of candidate substances on animals. It is crucial to design a strategic trial protocol to obtain clinical trial approval (IND) from the Ministry of Food and Drug Safety for clinical trials.

LCS is a specialized company whose main business purpose is consulting on the strategy and design of such non-clinical trials. It already has over 150 corporate clients and shows rapid growth every year.

By securing management rights of LCS, DreamCIS has completed vertical integration of clinical trials, from non-clinical trial strategy consulting to clinical trial plan approval, clinical trials, marketing authorization, and post-marketing surveillance.

Yoo Jeong-hee, CEO of DreamCIS, stated, "Securing management rights of LCS, a consulting company specializing in the non-clinical field, and the onboarding of expert CEO Lim Chae-sung will leave an important milestone for DreamCIS to leap forward as the global number one company."

Meanwhile, Lim Chae-sung, CEO of LCS, is a non-clinical trial expert who was responsible for research planning, KGLP certification, and management at ChemOn Co., Ltd., the first private GLP institution in Korea (non-clinical testing organization), for 16 years.

This content was produced with the assistance of AI translation services.